Systemic treatment in metastatic breast cancer (MBC), as in early stage breast cancer, is chosen on the basis of estrogen receptor (ER) and progesterone receptor (PR) status and overexpression/amplification of the human epidermal growth factor receptor 2 (HER2). The gene discussed is ESR1; the disease is breast cancer.